PRAME 301-309 (HLA-A*24)
( LYVDSLFFL )
#
| Sequence: | LYVDSLFFL | |
| Gene: | PRAME | |
| Delivery: | 1-3 days | |
| C-Terminus: | OH | |
| N-Terminus: | H | |
| Amount: | 1 mg | |
| Counter Ion: | TFA | |
| Protein: | Melanoma antigen preferentially expressed in tumors | |
| Species: | Human | |
| Allele: | HLA-A*24 | |
| Application : | Flow Cytometry | |
| Indication : | Cancer | |
| Purity : | 95% HPLC-MS |
Protocols and Tips
Data sheets
Safety data sheet poly peptides:
Special references for this product will come soon.
For your convenience, we have compiled a selection of publications
where our peptide products have been employed:
Publications >
For your convenience, we have compiled a selection of publications
where our peptide products have been employed:
Publications >
€105.00*
Delivery time 2-3 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS
Product number:
EP11836_1
More PRAME peptides
PRAME 100-108 (HLA-A*02:01)
( VLDGLDVLL )
From
€105.00*
The PRAME 100-108 peptide with the amino acid sequence VLDGLDVLL is a linear epitope (epitope ID 869501) derived from the Preferentially Expressed Antigen in Melanoma (PRAME, UniProt:P78395). It is used to stimulate human Prame (100-108)-specific CD8+T cells.
PRAME belongs to the cancer/testis antigens in Homo sapiens. This antigen is notably overexpressed in various solid tumors, including melanoma, epithelial ovarian cancer, multiple sarcoma subtypes, and non-small cell lung cancer, while its expression in healthy tissues is mostly restricted to the testes.
The PRAME 100-108 (VLDGLDVLL) epitope is presented by the MHC class I HLA-A*02:01 allele and was initially identified by Kessler et al. in 2001. In their studies, they demonstrated that cytotoxic T lymphocytes, which recognize this high-affinity binding epitope, could specifically target and lyse melanoma, lung, mammary, renal cell and cervical cancer cell lines.
PRAME 300–309 (HLA-A*02:01)
( ALYVDSLFFL )
From
€105.00*
ALYVDSLFFL is a linear peptidic epitope (epitope ID225231) studied as part of Melanoma antigen preferentially expressed in tumors from Homo sapiens (human), tested in T cell assays. Antigen Peptide PRAME 300–309 (HLA-A*02:01) ALYVDSLFFL for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.
PRAME 425-433 (HLA-A*02:01)
( SLLQHLIGL )
From
€105.00*
PRAME 425-433 (SLLQHLIGL) is a linear peptidic epitope (epitope ID 459114) studied as part of Preferentially Expressed Antigen in Melanoma (PRAME, UniProt:P78395), a cancer/testis antigen from Homo sapiens. PRAME is highly expressed in several solid tumors such as melanoma, epithelial ovarian cancer, multiple sarcoma subtypes and non-small cell lung cancer, while in healthy tissue it is almost exclusively restricted to the testicles. Therefore, it is a promising target for adoptive T cell therapies.
PRAME 425-433 (SLLQHLIGL) was first described by Kessler et al. in 2001. In their experiments, cytotoxic T lymphocytes recognizing the high affinity binding, HLA-A*0201–restricted PRAME epitope specifically lysed melanoma, renal cell, lung, mammary, and cervical carcinoma cell lines.
PRAME/OIP4 Peptide Pool, human
€285.00*
Pool of 125 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Melanoma antigen preferentially expressed in tumors (PRAME/OIP4) (UniProt ID: P78395) of Homo sapiens (Human).
One unit allows the stimulation of 2,5 x 108 cells.You can find applications and references in our blog post: Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I Expression